Skip to main content

Advertisement

Table 2 Change in HbA1c in new users of high-potency statins or low-potency statins as the control group

From: Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus

  High-potency statins Atorvastatin Pitavastatin Rosuvastatin Low-potency statins
With diabetes
 Number of patients 153 47 42 64 22
 Mean period (days)a 209 166 189 254 231
 HbA1c (%), mean ± SD      
  Before 7.18 ± 1.37 7.03 ± 1.31 7.57 ± 1.64 7.03 ± 1.17 6.95 ± 1.92
  After 7.57 ± 1.58 7.25 ± 1.21 8.11 ± 1.79 7.45 ± 1.61 7.25 ± 1.29
  Difference 0.39 ± 1.27 0.21 ± 0.75 0.54 ± 1.61 0.42 ± 1.32 0.30 ± 0.94
p-value 0.0002 0.05 0.04 0.01 0.15
Without diabetes
 Number of patients 165 49 31 85 10
 Mean period (days)a 239 212 310 229 236
 HbA1c (%), mean ± SD      
  Before 5.78 ± 0.38 5.76 ± 0.42 5.69 ± 0.24 5.81 ± 0.41 5.80 ± 0.47
  After 5.92 ± 0.45 5.95 ± 0.45 5.90 ± 0.48 5.92 ± 0.45 6.07 ± 0.58
  Difference 0.15 ± 0.31 0.19 ± 0.31 0.21 ± 0.46 0.10 ± 0.22 0.27 ± 0.18
p-value <0.0001 0.0001 0.02 <0.0001 0.001
p-valueb 0.02 0.89
  1. Abbreviations: SD standard deviation
  2. aDifference between statin start date and HbA1c measurement date
  3. bComparison of differences in HbA1c between diabetes and non-diabetes